Michal Ozery-Flato

Michal Ozery-Flato

Auto-generated profile, based on publicly available information

Michal Ozery-Flato

IBM Research-Israel, Haifa, Israel

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ATAnnelyse Thévenin
Annelyse Thévenin
LELiat Ein-Dor
Liat Ein-Dor
MOMichal Ozery-Flato
Michal Ozery-Flato
RSRon Shamir
Ron Shamir
Genomes undergo changes in organization as a result of gene duplications, chromosomal rearrangements and local mutations, among other mechanisms. In contrast to prokaryotes, in which genes of a common function are often organized in operons and reside contiguously along the genome, most eukaryotes show much weaker clustering of genes by function, except for few concrete functional groups. We set out to check systematically if there is a relation between gene function and gene organization in the human genome. We test this question for three types of functional groups: pairs of interacting proteins, complexes and pathways. We find a significant concentration of functional groups both in terms of their distance within the same chromosome and in terms of their dispersal over several chromosomes. Moreover, using Hi-C contact map of the tendency of chromosomal segments to appear close in the 3D space of the nucleus, we show that members of the same functional group that reside on distinct chromosomes tend to co-localize in space. The result holds for all three types of functional groups that we tested. Hence, the human genome shows substantial concentration of functional groups within chromosomes and across chromosomes in space.

1 April 2022 in Radiology
Verified
Journal Article
Closed access
YSYoel Shoshan
Yoel Shoshan
RBRan Bakalo
Ran Bakalo
FGFlora Gilboa-Solomon
Flora Gilboa-Solomon
VRVadim Ratner
Vadim Ratner
EBElla Barkan
Ella Barkan
LMLisa A. Mullen
Lisa A. Mullen
An artificial intelligence system filtered out cancer-free digital breast tomosynthesis examinations, led to lower recall rates, and reduced the number of examinations in the simulated workflow. Background Digital breast tomosynthesis (DBT) has higher diagnostic accuracy than digital mammography, but interpretation time is substantially longer. Artificial intelligence (AI) could improve re...

29 June 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
MOMichal Ozery-Flato
Michal Ozery-Flato
CLChaim Linhart
Chaim Linhart
LTLuba Trakhtenbrot
Luba Trakhtenbrot
SIShai Izraeli
Shai Izraeli
RSRon Shamir
Ron Shamir
Background: Chromosomal aneuploidy, that is to say the gain or loss of chromosomes, is the most common abnormality in cancer. While certain aberrations, most commonly translocations, are known to be strongly associated with specific cancers and contribute to their formation, most aberrations appear to be non-specific and arbitrary, and do not have a clear effect. The understanding of chromosomal aneuploidy and its role in tumorigenesis is a fundamental open problem in cancer biology. Results: We report on a systematic study of the characteristics of chromosomal aberrations in cancers, using over 15,000 karyotypes and 62 cancer classes in the Mitelman Database. Remarkably, we discovered a very high co-occurrence rate of chromosome gains with other chromosome gains, and of losses with losses. Gains and losses rarely show significant co-occurrence. This finding was consistent across cancer classes and was confirmed on an independent comparative genomic hybridization dataset of cancer samples. The results of our analysis are available for further investigation via an accompanying website. Conclusions: The broad generality and the intricate characteristics of the dichotomy of aneuploidy, ranging across numerous tumor classes, are revealed here rigorously for the first time using statistical analyses of large-scale datasets. Our finding suggests that aneuploid cancer cells may use extra chromosome gain or loss events to restore a balance in their altered protein ratios, needed for maintaining their cellular fitness.

1 March 2016 in Epilepsy & Behavior
Verified
Journal Article
Open access
ODOrrin Devinsky
Orrin Devinsky
CDCynthia Dilley
Cynthia Dilley
MOMichal Ozery-Flato
Michal Ozery-Flato
RARanit Aharonov
Ranit Aharonov
YGYa'Ara Goldschmidt
Ya'Ara Goldschmidt
PFPatty Fritz
Patty Fritz
A UCB-IBM collaboration explored the application of machine learning to large claims databases to construct an algorithm for antiepileptic drug (AED) choice for individual patients. Claims data were collected between January 2006 and September 2011 for patients with epilepsy > 16 years of age. A subset of patient claims with a valid index date of AED treatment change (new, add, or switch) were used to train the AED prediction model by retrospectively evaluating an index date treatment for subsequent treatment change. Based on the trained model, a model-predicted AED regimen with the lowest likelihood of treatment change was assigned to each patient in the group of test claims, and outcomes were evaluated to test model validity. The model had 72% area under receiver operator characteristic curve, indicating good predictive power. Patients who were given the model-predicted AED regimen had significantly longer survival rates (time until a treatment change event) and lower expected health resource utilization on average than those who received another treatment. The actual prescribed AED regimen at the index date matched the model-predicted AED regimen in only 13% of cases; there were large discrepancies in the frequency of use of certain AEDs/combinations between model-predicted AED regimens and those actually prescribed. Chances of treatment success were improved if patients received the model-predicted treatment. Using the model's prediction system may enable personalized, evidence-based epilepsy care, accelerating the match between patients and their ideal therapy, thereby delivering significantly better health outcomes for patients and providing health-care savings by applying resources more efficiently. Our goal will be to strengthen the predictive power of the model by integrating diverse data sets and potentially moving to prospective data collection.

1 April 2003 in Journal of Bioinformatics and Computational Biology
Verified
Journal Article
Closed access
PDF file
MOMichal Ozery-Flato
Michal Ozery-Flato
RSRon Shamir
Ron Shamir

1 January 2024 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
WLWen Li
Wen Li
SPSavannah Corrina Partridge
Savannah Corrina Partridge
DNDavid C. Newitt
David C. Newitt
JSJon Steingrimsson
Jon Steingrimsson
HMHelga S. Marques
Helga S. Marques
NHNola Hylton
Nola Hylton
Purpose To describe the design, conduct, and results of the Breast Multiparametric MRI for prediction of neoadjuvant chemotherapy Response (BMMR2) challenge. Materials and Methods The BMMR2 computational challenge opened on May 28, 2021, and closed on December 21, 2021. The goal of the challenge was to identify image-based markers derived from multiparametric breast MRI, including diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE) MRI, along with clinical data for predicting pathologic complete response (pCR) following neoadjuvant treatment. Data included 573 breast MRI studies from 191 women (mean age [±SD], 48.9 years ± 10.56) in the I-SPY 2/American College of Radiology Imaging Network (ACRIN) 6698 trial (ClinicalTrials.gov: NCT01042379). The challenge cohort was split into training (60%) and test (40%) sets, with teams blinded to test set pCR outcomes. Prediction performance was evaluated by area under the receiver operating characteristic curve (AUC) and compared with the benchmark established from the ACRIN 6698 primary analysis. Results Eight teams submitted final predictions. Entries from three teams had point estimators of AUC that were higher than the benchmark performance (AUC, 0.782 [95% CI: 0.670, 0.893], with AUCs of 0.803 [95% CI: 0.702, 0.904], 0.838 [95% CI: 0.748, 0.928], and 0.840 [95% CI: 0.748, 0.932]). A variety of approaches were used, ranging from extraction of individual features to deep learning and artificial intelligence methods, incorporating DCE and DWI alone or in combination. Conclusion The BMMR2 challenge identified several models with high predictive performance, which may further expand the value of multiparametric breast MRI as an early marker of treatment response. Clinical trial registration no. NCT01042379 Keywords: MRI, Breast, Tumor Response Supplemental material is available for this article. © RSNA, 2024.